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Abstract
The pupose of this study was to determine the viability of cell-based delivery of brain-derived
neurotrophic factor (BDNF) from genetically modified mesenchymal stem cells (MSCs) for
neuroprotection of RGC-5 cells. RGC-5 cells were differentiated with the protein kinase inhibitor
staurosporine (SS) and exposed to the cellular stressors glutamate or H2O2. As a neuroprotective
strategy, these cells were then co-cultured across a membrane insert with mesenchymal stem cells
(MSCs) engineered with a lentiviral vector for production of BDNF (BDNF-MSCs). As a positive
control, recombinant human BDNF (rhBDNF) was added to stressed RGC-5 cells. After SS
differentiation RGC-5s developed neuronal-like morphologies, and a significant increase in the
proportion of RGC-5s immunoreactive for TuJ-1 and Brn3a was observed. Differentiated RGC-5s
also had prominent TrkB staining, demonstrating expression of the high-affinity BDNF receptor.
Treatment of SS differentiated RGC-5s with glutamate or H2O2, produced significant cell death (56.0
± 7.02 and 48.90 ± 4.58% of control cells, respectively) compared to carrier-solution treated cells.
BDNF-delivery from MSCs preserved more RGC-5 cells after treatment with glutamate (80.0 ±
5.40% cells remaining) than control GFP expressing MSCs (GFP-MSCs, 57.29 ± 1.89%, p < 0.01).
BDNF-MSCs also protected more RGC-5s after treatment with H2O2 (65.6 ± 3.47%) than GFP-
MSCs (46.0 ± 4.20%, p < 0.01). We have shown survival of differentiated RGC-5s is reduced by the
cellular stressors glutamate and H2O2. Additionally, our results demonstrate that genetically
modified BDNF-producing MSCs can enhance survival of stressed RGC-5 cells and therefore, may
be effective vehicles to deliver BDNF to retinal ganglion cells affected by disease.
Keywords
Neuroprotection; Mesenchymal Stem Cells; BDNF; Glaucoma; Ganglion Cells; RGC-5
Corresponding Author: Donald Sakaguchi, 503 Science Building II, Ames Iowa, 50011. Ph: 515-294-3112, Email: dssakagu@iastate.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Exp Eye Res. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
Exp Eye Res. 2009 October ; 89(4): 538–548. doi:10.1016/j.exer.2009.05.013.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
Glaucoma is a progressive, chronic, optic neuropathy that is characterized by retinal ganglion
cell (RGC) death, and subsequent loss of visual function. Several studies suggest secondary
degeneration of RGCs in optic neuropathies can be mediated, in part, via glutamate
excitotoxicity1-4, as well as the presence of excessive reactive oxygen species (ROS), which
are capable of inducing DNA damage, the oxidative modification of proteins and cellular
dysfunction resulting in cell death5-8. Developing neuroprotective approaches that can
preserve cells following insult with these compounds is an important step in developing long-
term treatments for optic neuropathies.
Studying optic neuropathies requires reproducible and reliable models9. While these models
have proved invaluable for researchers, the cost of animal care, as well as the labor involved
in generating the models and carrying out the experiments is prohibitive to high-throughput
assays of potential neuroprotective compounds. Thus, developing relevant in vitro assays for
evaluating the potential neuroprotective effects of different pharmacological compounds or
cell-based strategies is a useful and powerful approach in developing treatment strategies,
which can be tested in vivo. The RGC-5s are a transformed retinal ganglion cell line that retain
some characteristics of retinal ganglion cells10. The RGC-5s initially proved useful in modeling
the apoptotic events of RGCs with respect to serum deprivation11, oxidative stress12, glutamate
excitotoxicity13, as well as cell death resulting from hydrostatic pressure14. While the rapid
proliferation of these cells facilitates expansion of the cell line, it creates difficulties analyzing
neuroprotection experiments, as the presence of mitotic cells confounds the results. Recently,
Frassetto et al. demonstrated that transient treatment of RGC-5s with staurosporine (SS)
induced them to become highly branched cells, with some electrophysiological and phenotypic
characteristics similar to RGCs15. With this advance it is now possible to use RGC-5s as a
model for retinal ganglion cell damage assays to evaluate potential neuroprotective factors and
delivery systems in a reproducible manner, without the confounding variables that highly
mitotic cells would introduce into these types of experiments.
A candidate for neuroprotection of RGCs in glaucomatous eyes is brain-derived neurotrophic
factor (BDNF), a 14 kDa protein16 that predominately signals through its high affinity TrkB
receptor17. Brain-derived neurotrophic factor has been shown to be essential for correct RGC
development18, 19, and survival of RGCs in vitro20, 21. Bolus injections of BDNF have proven
neuroprotective for retinal neurons in different disease models, as well as optic nerve
axotomy22-28. Additionally, viral mediated transfer of BDNF has been shown to be
neuroprotective for RGCs in models of glaucoma29, 30. While these results are encouraging,
it is important to address the prolonged delivery of BDNF, since frequent and repeated
injections into the eye may not be a viable treatment option for chronic optic neuropathies.
Therefore, it is essential to develop a minimally invasive treatment that is capable of prolonged
delivery of BDNF to disease-compromised optic nerves.
We have investigated a cell-based delivery strategy to provide BDNF, or other neuroprotective
factors, to glaucomatous eyes (Sakaguchi DS, et al. IOVS 2007;48: ARVO E-Abstract 1303).
Mesenchymal stem cells (MSCs) are an excellent choice as cellular vehicles to deliver BDNF
to damaged retinas. These multipotent cells are easily isolated31, display significant
plasticity32 and may provide a source for cells that can be engineered for autologous transplants.
Mesenchymal stem cells bypass the ethical concerns typically associated with embryonic, fetal,
and neonatal derived cells, and the difficulty associated with deriving adult progenitors from
CNS tissues. In addition, MSCs have the ability to survive and migrate when transplanted to
CNS tissues33-37, differentiate into neural-like cells in vitro33, 37-39, and display
electrophysiological properties consistent with mature neurons40, 41. Furthermore, naïve MSCs
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have also shown the potential to be neuroprotective when transplanted into models of retinal
degeneration42-44. Together, these studies indicate that MSCs are excellent candidates for
genetic engineering and autologous transplants into damaged CNS environments.
The purpose of this study was to demonstrate the feasibility of using MSCs to deliver BDNF
in an attempt to rescue RGC-5s exposed to different cellular insults. We have demonstrated
that BDNF released from MSCs engineered with a lentiviral vector was sufficient to protect
RGC-5s from glutamate- or H2O2-mediated cell loss. To substantiate our observations,
rhBDNF was added to SS differentiated RGC-5s treated with the cellular stressors and
produced similar protection of RGC-5s. Taken together, these results demonstrate RGC-5s can
serve as a model of retinal ganglion cells, and that cell-based delivery of neuroprotective factors
from engineered MSCs has important clinical implications for treatment of different forms of
optic neuropathies.
Materials and Methods
RGC-5 Maintenance and Differentiation
The RGC-5 cells (a generous gift from Dr. N. Agarwal, University of North Texas Health
Science Center, Fort Worth, TX) were maintained as an adherent cell line in uncoated T-75
tissue culture flasks. RGC-5s were grown in medium containing DMEM (1 g glucose/ L,
Gibco) 10% fetal bovine serum (FBS; SH30071.03, Hyclone, Logan, UT), L-glutamine (4 mM,
25038-081, Gibco, Grand Island, NY) and a penicillin (100 U/mL)/ streptomycin (100 μg/mL)
solution (P0781, Sigma, St. Louis, MO). Cells were grown to 80% confluency and were gently
lifted from the flask using 2 mL 0.05% Trypsin-EDTA solution (25300-054, Gibco) and placed
in a 37°C incubator for 30 seconds. Trypsin was diluted with fresh medium, and RGC-5s were
centrifuged at 800g for 5 minutes to pellet the cells. Pellets were re-suspended in fresh medium
and split into new flasks at a ratio of 1:10. RGC-5 cultures were fed every other day by
supplementing the flask with fresh medium.
RGC-5s were induced to differentiate into highly branched, non-mitotic cells using a protocol
developed by Frassetto et al15. Briefly, RGC-5s were cultured as previously described and
plated onto glass coverslips coated with an entactin-collagen-laminin substrate (ECL, 10 μg/
mL, 08-110, Chemicon, Temecula, CA). Cells were allowed to adhere to the coverslip for 1
hour at 37°C. Cells were subsequently treated with the general kinase inhibitor staurosporine
(1 μM, ALX-380-014-C100, Alexis, San Diego, CA) for 1 hour. Following differentiation,
medium was changed and RGC-5 cells were grown an additional 3 days and analyzed for
expression of neuronal markers using immunocytochemistry, or used immediately for
subsequent experiments.
Bromo-deoxyuridine Incorporation Analysis
Control or SS-differentiated RGC-5s were incubated with 5 μM Bromo-deoxyuridine (BrdU)
for 6 hours. BrdU containing medium was removed, fresh medium added, and cells were
allowed to grow overnight. Cells were then fixed with 4% paraformaldehyde in 0.1 M PO4
buffer (pH 7.4). Following rinses in phosphate-buffered saline (PBS; 137 mM NaCL, 2.68 mM
KCl, 10.14 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.2) cells were incubated in 2 N HCl for 15
minutes at 37° C. HCl was neutralized by incubation with 0.1 M sodium borate for 15 minutes
at room temperature. BrdU incorporation was detected with an anti-BrdU antibody (1:250,
Accurate Chemical, Westbury, NY). The number of BrdU immunolabeled cells was counted
in 5 fields on each coverslip at 10× magnification. The percentage of BrdU positive cells was
calculated by dividing the total number of BrdU immunoreactive cells by the total number of
cells as determined from nuclear counterstaining using 4′, 6′-diamidino-2-phenylindole,
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dilactate (DAPI, 1 μg/ mL, D3571, Sigma). This analysis was performed from three separate
culture sessions.
Rat Mesenchymal Stem Cells
Rat MSCs (Tulane Center for Gene Therapy, New Orleans, LA) were maintained as an adherent
cell line in α-MEM medium (12561-049, Invitrogen) containing 20% hybridoma qualified FBS
(S11595, Atlanta Biologicals, Norcross, GA), 2 mM L-glutamine, and antibiotic-antimycotic
(1%, 15240-096, Invitrogen; 10,000 U/mL penicillin, 10,000 μg/mL streptomycin, 25 ng/mL
amphotericin B). Cells were maintained as low-density cultures plated at 75-150 cells/ cm2.
When cultures reached 70-80% confluency MSCs were gently lifted from the dish using 0.25%
trypsin, 0.1% EDTA solution (Invitrogen), and pelleted at 800g. MSCs were subsequently
plated into 150 mm culture dishes at 75-150 cells/ cm2. Cultures were fed by supplementing
the dish with fresh medium every other day.
Engineering Stem Cells Ex-Vivo with Lentiviral Vectors
Mesenchymal stem cells were engineered to produce and secrete the neurotrophic factor BDNF
using lentiviral vectors. Briefly, MSCs were plated in 6 well plates at a density of 1000-1200
cells per well and allowed to adhere for 12 hours. After adhering to the plate the growth medium
was substituted in each well with α-MEM containing 2% FBS and 12 μg/ml sequabrene
(152667, Sigma). Two separate lentiviral constructs encoding 1) BDNF (LV-BDNF) and 2)
green fluorescent protein (GFP, LV-GFP) were added simultaneously to MSCs at a multiplicity
of infection (MOI) of 15 for each construct. A population of control MSCs was engineered
with only the LV-GFP vector at an MOI of 30 to match the viral titer of the BDNF/GFP
engineered MSCs. Viral particles were removed after 8 hours of exposure, and medium was
changed to fresh growth medium. Engineered MSCs were subsequently maintained as
previously described.
Neurotrophin Bioactivity Assay
All animal studies were conducted in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research, and had approval of the Iowa State University
Institutional Animal Care and Use Committee. Primary explant cultures of rat embryonic day
17 (E17) dorsal root ganglia (DRG) were used to assess the bioactivity of BDNF released from
MSCs, as DRG have been shown to elongate neurites in response to BDNF exposure45, 46.
Briefly, E17 rat pups were anesthetized by hypothermia, decapitated, rinsed in ice-cold 70%
ethanol and subsequently placed in ice-cold DMEM. Lumbar DRG were dissected from
isolated spinal cords and pooled in ice-cold L-15 medium (21683-027, Invitrogen). Following
dissection, DRG were rinsed with ice-cold L15 and transferred to warm DRG growth medium
containing DMEM, L-glutamine, penicillin-streptomycin, and 10% FBS. Three to four DRG
explants were transferred in approximately 75 μL of medium onto poly-L-ornithine coated 12
mm coverglass placed into wells of 24 well culture plates. DRG were allowed to adhere for 8
hours, and wells were subsequently flooded with experimental medium. Four different media
conditions were tested: 1) MSC growth medium only, 2 and 3) MSC medium conditioned by
BDNF-MSCs or GFP-MSCs, or 4) MSC medium containing 100 ng/ mL recombinant human
BDNF (rhBDNF, 450-02, Peprotech, Rocky Hill, NJ). Explants were allowed to grow for an
additional 48 hours, and subsequently fixed with 4% paraformaldehyde (pH 7.4). To visualize
and quantify neurite outgrowth, cultures were stained with an anti-neurofilament antibody
(RMO.308, 1:50, Virginia Lee, University of Pennsylvania), as described in the next section.
Images of each DRG were captured using a 10× objective, and montage images were prepared.
Each montage image was presented to naïve observers in order to judge the extent and density
of neurite outgrowth in each condition. Each DRG was scored on a scale from 1-5; with 1
representing little neurite growth in terms of length and density, and 5 representing long, dense
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neurite arborizations from the DRG. Data from this analysis were pooled and statistical analysis
was performed using one-way ANOVA with Dunnet's post-test.
Immunocytochemical Analysis
Cultures were fixed with 4% paraformaldehyde (in 0.1 M PO4 buffer), rinsed in filtered PBS,
and incubated in blocking solution containing 5% normal donkey serum (NDS, 017-000-121,
Jackson ImmunoResearch, West grove, PA), 0.04% bovine serum albumin (BSA, A9647,
Sigma), and 0.04% Triton X-100 to eliminate non-specific antibody labeling. Coverslips were
incubated in the primary antibodies: anti-TuJ-1 (1:250, R&D Systems, Minneapolis, MN),
anti-Brn3a (1:100, Chemicon), anti-TrkB (1:100, Santa Cruz, Santa Cruz, CA), or anti-BDNF
(1:100, Santa Cruz), diluted in blocker overnight at 4°C. Coverslips were then rinsed in PBS
containing 0.1% Triton X-100. A donkey anti-mouse Cy-3 conjugated secondary antibody
(1:150, 711-175-152, Jackson ImmunoResearch), was applied for 2 hours, and subsequently
rinsed in filtered PBS. DAPI (1 μg/mL, Sigma) and Alexa-488 Phalloidin (5 U/mL A-12379,
Molecular Probes, Eugene, OR) were diluted in PBS containing 0.04% Triton X-100 and
incubated for 30 min at room temperature in order to visualize nuclei and the F-actin
cytoskeleton, respectively. Coverslips were subsequently rinsed with PBS and mounted in
Vectashield (H-1000, Vector Laboratories, Burlingame, CA) anti-fade mounting media and
sealed with fingernail polish. Negative controls were processed in parallel by omission of the
primary or secondary antibody, and no signal was detected. Images of cells were captured using
a Nikon Microphot fluorescent microscope (Nikon, Melville, NY). Micrographs were captured
using a MegaPlus digital camera (Kodak, Rochester, NY) and images prepared using Adobe
Photoshop (Ver. 9.0, Adobe, San Jose, CA) and Macromedia Freehand (Ver. 10.0,
Macromedia, San Francisco, CA).
Glutamate- and Hydrogen Peroxide-Mediated Cell Death
L-glutamic acid (glutamate, 49449, Sigma), and hydrogen peroxide (H2O2, H325-500, Fisher),
were used in these studies to induce cell death in differentiated RGC-5 cells. Staurosporine
differentiated RGC-5 cells were exposed to varying concentrations of glutamate (50 μM - 1.4
mM), or hydrogen peroxide (10-300 μM) for 8 hours. Media were replaced with fresh growth
media and cells grown for an additional 2 days. Glutamate treated cells, and their respective
control cells, were exposed to buthionine sulfoximine (BSO, B2640, Sigma) following SS
differentiation until the completion of the experiment to deplete cellular glutathione levels13,
in order to make the cells more susceptible to glutamate induced stress. Cells were fixed with
4% paraformaldehyde in 0.1 M PO4 and stained with Alexa-488 Phalloidin (5 U/ mL,
Molecular Probes) in order to visualize the F-actin cytoskeleton. A blinded observer imaged
5 regions of each coverslip at pre-defined areas, and quantified the percentage of cells present
on each coverslip as compared to control, vehicle treated RGC-5 cells. The concentration at
which approximately 50% of RGC-5s were present compared to controls, was used for all
subsequent experiments. Each experiment in these series of studies was conducted three times,
with at least two replicates per timepoint for each experiment. Results were analyzed
statistically using one-way ANOVA with Bonferroni's test for multiple comparisons.
Cell death was verified by staining H2O2 or glutamate treated cells with membrane-
impermeable Sytox DNA stain (S7020, Invitrogen), which labels cells undergoing cell death.
Briefly, SS treated RGC-5s were subjected to H2O2 or glutamate treatment as previously
described. Following treatment, cells were exposed to 15 nM Sytox for 30 minutes at 37°C,
fixed with 4% paraformaldehyde, and counterstained with DAPI. Cells were imaged and the
proportion of cells labeled with Sytox was determined for H2O2-, glutamate-treated, and
control cells. Student's t-test was used to analyze control and experimental conditions.
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Co-Culturing Lentiviral Transduced MSCs with Differentiated RGC-5s
Genetically engineered MSCs secreting BDNF, or control MSCs expressing GFP were
generated as previously described. Engineered MSCs were plated into Transwell culture inserts
with 0.4 μm diameter semi-permeable membranes (07-200-147, Fisher) in 24 well plates at a
density of 452 cells/ mm2. RGC-5s were differentiated as previously described in separate
dishes on entactin-collagen-laminin (ECL, 10 μg/ mL, Chemicon) coated glass coverslips.
Following differentiation, RGC-5s were transferred and grown in the presence of BDNF-MSCs
or GFP-MSCs for 24 hours directly below the insert in the lower chamber. Following this initial
period, cellular stressors were added to the co-cultures for 8 hours. Media were changed to
fresh growth media, and cells were grown for an additional 48 hours in the presence of
engineered MSCs. To serve as a positive control, a dose-response analysis of purified rhBDNF
(Peprotech) was performed, based on concentrations previously reported to be effective in
eliciting responses from cultured RGCs21, 47. The lowest concentration that resulted in
significantly more cells than glutamate- or H2O2- treated RGC-5 cells (100 ng/mL) was placed
in the medium of some chambers immediately, and remained throughout the course of the
insult. Surviving cells were analyzed as previously described for each of three experiments,
with at least two replicates per experiment.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism (Ver. 3.0, GraphPad Software,
San Diego, CA).
Results
Staurosporine-induced differentiation of RGC-5s
Development of in vitro systems that model RGCs and permit screening of potential
neuroprotective compounds is paramount to developing new treatments for glaucoma. Naïve,
undifferentiated RGC-5s have elongated, simple morphologies with few processes emanating
from the cell body 24-72 hours following plating (Fig. 1 A-C). When RGC-5s were treated
with SS they elaborated extensive processes within 24 hours following treatment, and
maintained these complex morphologies up to 72 hours in culture (Fig 1. D-F). While SS-
treated RGC-5s displayed complex morphologies reminiscent of retinal neurons, we sought to
determine if these cells were capable of expressing neuron-specific class III β-tubulin (TuJ-1
antibody labeling), and the RGC specific transcription factor Brn3a, that are expressed by
RGCs in vivo. Figure 2 illustrates extensive TuJ-1 immunoreactivity (IR) in the neurites (Fig.
2 A) and cell bodies, whereas RGC-5s treated with carrier solution expressed very low levels
of TuJ-1-IR. Differentiated RGC-5s also expressed Brn3a in the cell soma (Fig. 2 B, arrow),
while low levels of Brn3a-IR were detected in undifferentiated RGC-5s (Fig. 2 D). The
proportion of RGC-5s expressing IR for each antibody was quantified, and it was determined
that 70.26 ± 8.37% (±S.E.M.) of SS- differentiated RGC-5s expressed TuJ-1, a significant
increase from 13 ± 1.3% of control RGC-5s (Fig. 2 E, p < 0.0001). Furthermore, SS
differentiated RGC-5s also displayed a higher incidence of Brn3a immunoreactive cells, with
17.36 ± 5.57% of SS treated RGC-5s expressing Brn3a-IR, compared to just 1.06 ± 0.82% of
control RGC-5s (Fig. 2 E, p < 0.05). A BrdU incorporation analysis was used to determine the
percentage of mitotic cells in SS-treated vs. untreated populations of RGC-5s. Undifferentiated
RGC-5s were a highly mitotic population of cells, with 66.7 ± 1.91% of RGC-5s
immunoreactive for anti-BrdU following a 6 hour BrdU pulse (Fig. 2 F). In contrast, SS-
differentiated RGC-5s had significantly less BrdU uptake, with only 4.62 ± 0.76% of cells
BrdU immunoreactive following differentiation (Fig. 2 F, p < 0.0001). These results
demonstrate that SS-differentiated RGC-5s display a decreased proliferative capacity and
develop complex morphologies consistent with retinal neurons. In addition, they express
neuronal markers consistent with RGCs in vivo.
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Engineering MSCs Ex Vivo
Engineering mesenchymal stem cells (MSCs) ex vivo is an important strategy for a cell-based
delivery of neurotrophic factors to compromised retinal neurons. Mesenchymal stem cells were
engineered to produce and secrete BDNF using lentiviral vectors. Immunocytochemical
analysis of engineered MSCs revealed modest IR for BDNF in control MSCs (GFP-MSCs)
within the nucleus and cell body (Fig. 3 A, B). In contrast, robust BDNF-IR was observed in
the perinuclear region and cell body of LV-BDNF transduced MSCs (BDNF-MSCs),
demonstrating the effectiveness of the lentiviral constructs in transducing these cells (Fig. 3
C, D). We examined the cellular localization of the high affinity BDNF receptor, TrkB, in
control and SS differentiated RGC-5s to determine if RGC-5s express the receptor necessary
for BDNF to elicit a response. Control RGC-5s had diffuse TrkB-IR throughout the entire cell
(Fig. 3 E, F). However, upon SS-differentiation RGC-5s displayed intense TrkB-IR in the cell
body and base of the processes (Fig. 3 G, H).
To determine whether the secreted BDNF was bioactive, the length and density of neurites
emanating from E17 dorsal root ganglion (DRG) cultures were judged by blind observers
following treatment with experimental media. Upon treatment with normal MSC growth
medium the DRG displayed modest neurite outgrowth (Fig. 4 A, E), which was also observed
for DRG exposed to GFP-MSC conditioned media (CM) (Fig. 4 B, E). No significant difference
(Fig. 4 E, p > 0.05) was observed in terms of DRG neurite outgrowth scores when comparing
the two control conditions, MSC media (1.87 ± 0.27) and GFP-MSC CM (1.70 ± 0.24). In
contrast, DRG that were grown in the presence of BDNF-MSC CM (Fig. 4 C) and DRG treated
with 100 ng of rhBDNF (Fig. 4 D) displayed extensive neurite outgrowth. Although DRG
treated with BDNF-MSC CM (3.02 ± 0.31), or rhBDNF (3.49 ± 0.24) did not differ in the
extent of neurite outgrowth (Fig. 4 E, p > 0.05), these two treatment groups displayed
significantly more neurite outgrowth than DRG treated with MSC media alone, or GFP-MSC
CM (Fig. 4 E, p < 0.05). These results demonstrate that MSCs engineered with a lentiviral
BDNF vector produced and released bioactive BDNF that stimulated extensive neurite
outgrowth. Furthermore, SS differentiated RGC-5s expressed the necessary receptor to mediate
BDNF signaling.
Glutamate- and ROS-induced RGC-5 Death
We sought to determine if differentiated RGC-5s would respond to the cellular stressors
glutamate and hydrogen peroxide, which have been implicated in RGC death in glaucomatous
eyes. We have shown that glutamate concentrations greater than 800 μM induced significant
death of RGC-5, as compared to RGC-5s not exposed to glutamate (Fig. 5 A, p < 0.01). For
subsequent experiments 1 mM glutamate was used as only 56.0 ± 7.92% (± S.E.M.) of RGC-5s
were present after treatment. In addition, we have shown H2O2 to be a potent cellular stressor,
with concentrations greater than 10 μM inducing significant RGC-5 death (Fig. 5 B, p < 0.001).
For subsequent experiments 10 μM H2O2 was used as only 48.90 ± 4.58% of RGC-5s were
present, as compared to carrier-solution treated cells. In order to determine if BDNF could
prevent loss of RGC-5s following treatment with glutamate or H2O2, rhBDNF was applied to
cultures throughout the period of stressor insult, and once after treatment. It was determined
that rhBDNF concentrations greater than 100 ng/ mL were sufficient to attenuate glutamate
mediated RGC-5 loss, protecting 87.77 ± 7.42% of RGC-5s, a significant increase from 60.60
± 3.13% of RGC-5s present in cultures treated with glutamate only (Fig. 5 C, p < 0.05). Addition
of rhBDNF also prevented RGC-5 cell loss due to H2O2 treatment at concentrations greater
than 100 ng/ mL. This application of rhBDNF showed 70.0 ± 14.81% of RGC-5s present, with
only 48.88 ± 4.58% of cells present in H2O2 treated cultures (Fig. 5 D, p < 0.05). Cell death
of RGC-5s was verified by application of Sytox following treatment with glutamate or
H2O2. We have shown that 14.27 ± 3.01% of control RGC-5s were labeled with Sytox, while
48.61 ± 7.02 % and 53.99 ± 5.12 % of H2O2 and glutamate treated cells were labeled,
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respectively (Fig. 5 E, p < 0.0001). Taken together these results demonstrate cell death can be
induced in RGC-5s with glutamate and H2O2, factors implicated in secondary degeneration of
ganglion cells in glaucomatous eyes. Furthermore, we have demonstrated that application of
rhBDNF during the time of cellular insult can attenuate RGC-5 death induced by glutamate
and H2O2.
Delivery of BDNF to RGC-5s from Genetically Modified MSCs
Finally, we sought to determine if BDNF released from MSCs was able to protect SS-
differentiated RGC-5s following treatment with glutamate or H2O2. We have shown that after
glutamate treatment 54.0 ± 5.99% (± S.E.M.) of RGC-5s remained, a significant decrease from
non-treated RGC-5s (Fig. 6 A-C, p < 0.001). We have also demonstrated significant protection,
with 81 ± 3.20% of RGC-5s present after treatment with rhBDNF (Fig. 6 A, p < 0.001). Delivery
of BDNF from BDNF-MSC co-cultures also proved very effective in attenuating RGC-5 cell
death, with 80 ± 5.40% of RGC-5s present following glutamate treatment (Fig. 6 A, D), which
was significantly more than the 57.29 ± 1.89% remaining in RGC-5 co-cultures with MSCs
transduced with only the LV-GFP vector (Fig. 6 A, E, p < 0.01). Cellular based rescue
experiments were also carried out using H2O2 to induce RGC-5 death. We observed a
significant decrease in remaining RGC-5s as compared to control cells when RGC-5s were
exposed to H2O2 (Fig. 7 A-C, p < 0.001), as previously shown. Moreover, addition of rhBDNF,
as well as co-culturing with BDNF-MSCs produced a protection of RGC-5s, with 68.67 ±
3.33% and 65.6 ± 3.47% of cells remaining, respectively (Fig. 7 A, D). This was significantly
greater than the 46.0 ± 4.20% of cells remaining in GFP-MSC co-cultures (Fig. 7 A, E, p <
0.01). Taken together these results demonstrate that MSCs genetically modified for production
of BDNF are reliable cellular vehicles for delivering neuroprotective substances to
compromised cells.
Discussion
Staurosporine-differentiated RGC-5s develop into highly branched cells that morphologically
resemble cultured retinal ganglion cells, consistent with findings presented by Frassetto et
al15. Under these differentiation conditions few RGC-5s incorporated BrdU, indicating a
significant decrease in cell proliferation. We have shown a morphological differentiation of
RGC-5s from simple cells into highly branched, complex cells consistent with mature RGCs.
In addition, greater numbers of RGC-5s were immunolabeled with the neuronal markers TuJ-1
and Brn3a following differentiation. We have also shown a shift in the cellular distribution to
the cell body for the high affinity BDNF receptor, TrkB. This receptor is essential for correct
retinal ganglion cell development18, 19 and survival20, 21, and we propose that the expression
of this receptor by RGC-5s indicates these cells are assuming a more mature phenotype
following differentiation.
We investigated the potential use of the SS-differentiated RGC-5 cells as an in vitro system to
model ganglion cell death accompanying glaucoma. In these studies the cellular stressors
glutamate and H2O2, which have been implicated in glaucomatous secondary degeneration of
RGCs1-5, 7, 8, induce RGC-5 cell death, as compared to vehicle-treated RGC-5s. Previous
experiments using undifferentiated RGC-5s have modeled the apoptotic response of RGC-5s
to serum deprivation11, oxidative stress12, glutamate excitotoxicity13, and hydrostatic
pressure14. While these earlier experiments have demonstrated that undifferentiated RGC-5s
are a useful model for ganglion cells, it is not clear if SS-differentiated RGC-5s would respond
in a similar or different fashion. We have demonstrated SS-differentiated RGC-5s can express
proteins consistent with differentiated ganglion cells and thus can serve as a non-mitotic model
of in vivo RGCs. Furthermore, we have demonstrated a dramatic decrease in numbers of
differentiated RGC-5s after treatment with the cellular stressors glutamate and H2O2. In
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addition to susceptibility to the cellular stressors glutamate and H2O2, RGC-5s have also been
shown to express complement proteins48, and have mitochondrial abnormalities49, which are
each prevalent in eyes with optic neuropathies50, 51.
In these experiments we have demonstrated that rhBDNF can prevent SS-differentiated RGC-5
loss mediated by glutamate and H2O2. BDNF has been shown to prevent oxidative damage in
retinal52, brain53 and auditory54 neurons, which is hypothesized to occur by secondary
upregulation of other neuroprotective factors52 or by increasing cellular GSH to combat ROS
damage54. BDNF has clearly been linked as a candidate neuroprotectant to eyes with
glaucomatous optic neuropathies. Additionally, BDNF has been shown to be neuroprotective
in primary cultured RGCs55, and when delivered via engineered astrocytes56. In vivo
experiments have demonstrated that transfected Müller glia57 are neuroprotective in models
of optic nerve axotomy. Furthermore, intracerebral injections of BDNF-producing lentiviral
vectors in excitotoxic models of brain damage were neuroprotective58. We have shown similar
neuroprotection in SS-differentiated RGC-5 cells, demonstrating their ability to model RGCs.
BDNF and its receptor TrkB are expressed by ganglion cells in the neural retina59, and BDNF
is retrogradely transported to the retina18, 60, 61. It has previously been shown that in
glaucomatous eyes the retrograde transport of BDNF from the superior colliculus via the RGC
axons is severely diminished62, 63. We hypothesize that prolonged delivery of BDNF to
glaucomatous eyes may prevent RGC degeneration, as the loss of trophic support is likely one
of the causes of neurodegeneration. The results we have presented here are encouraging, as
BDNF delivered from engineered MSCs was able to attenuate the loss of the RGC-5s following
glutamate or H2O2 insults. These results are consistent with previous studies that demonstrate
lentiviral transduced MSCs are able to survive and express transgenes following
transplantation64. While our results suggest this is a feasible approach in the retina, further in
vivo experimentation needs to be conducted.
We have demonstrated that MSCs are a useful cellular delivery vehicle capable of providing
neuroprotection to compromised RGC-5s by release of BDNF. We feel that MSC-based
delivery systems have the potential for use in clinical settings as MSCs are easily engineered,
and can be used in an autologous fashion, which makes immune-mediated rejection of the
transplanted cells less likely. Additionally, MSCs are easily isolated in large quantities as
compared to adult CNS progenitors, and bypass the moral and ethical concerns typically
associated with embryonic, fetal, and neonatal stem/progenitor cell isolation. Transplantation
of genetically modified MSCs to produce neurotrophic growth factors may be a useful strategy
for treatment of different forms of optic neuropathies in the future.
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Figure 1.
Differentiation of RGC-5s with staurosporine (SS). Control, carrier solution treated RGC-5s
at 24 (A), 48 (B), or 72 (C) hours after plating had simple, flat morphologies. In contrast,
differentiation of RGC-5s with 1 μM SS for 1 hour induced RGC-5s to become highly branched
cells 24 (D), 48 (E), or 72 (F) hours post-treatment.
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Figure 2.
Staurosporine differentiation upregulates neuronal marker expression in RGC-5s.
Differentiated RGC-5s were highly immunoreactive for the phenotypic neuronal marker TuJ-1
in the processes (A, arrows) and cell body. In addition, SS differentiated RGC-5s were
immunoreactive for the RGC transcription factor Brn3a (B, arrow). In contrast,
undifferentiated, control RGC-5s expressed TuJ-1 (C, arrow) and Brn3a (D, arrow) at relatively
low levels. Quantification of the number of SS-treated RGC-5s expressing phenotypic markers
revealed a significant increase from 13.0 ± 1.3 % (± S.E.M.) in control RGC-5s to 70.26 ± 8.37
% in SS differentiated RGC-5s for TuJ-1 (E, p < 0.0001). This trend was also observed for
Brn3a expression patterns, with a significant increase from 1.06 ± 0.82 % of control RGC-5s
expressing Brn3a to 17.36 ± 5.57 % of differentiated RGC-5s immunoreactive for Brn3a (E,
p < 0.05). Finally, BrdU analysis revealed that only a small proportion of the differentiated
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RGC-5s incorporated BrdU (4.62 ± 0.76 %), a significant decrease from 66.7 ± 1.91 % of
undifferentiated RGC-5s, (F, p < 0.0001).
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Figure 3.
Successful transduction of mesenchymal stem cells (MSCs) using lentiviral vectors. MSCs
were transduced with lentiviral vectors encoding green fluorescent protein (GFP-MSC; A, B)
or brain-derived neurotrophic factor (BDNF-MSC; C, D). Transduced cells were probed with
anti-BDNF antibodies. A low level of BDNF was detected in the peri-nuclear region (A, arrow),
and cell body (A, arrowhead) of GFP-MSC controls. This control population of MSCs had
high expression of GFP (B). Merged image of GFP and BDNF immunoreactivity (B)
demonstrates the cellular localization of BDNF. In contrast to control cells, BDNF-MSCs had
increased levels of BDNF-IR in the perinuclear area (C, arrows), in addition to the cell body
(C, arrowhead). Merged images also revealed high levels of GFP expression (D), which
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demonstrates the localization of BDNF-IR in the cell. Control and differentiated RGC-5s were
examined to determine if the high affinity BDNF receptor TrkB was present. Undifferentiated
RGC-5s had high expression of TrkB in the perinuclear region (E, arrows), and in distal parts
of the cell (E, arrowhead). TrkB immunoreactivity (IR), merged with the Alexa-488 phalloidin
stained cytoskeleton demonstrates the cellular localization of TrkB (F). Differentiated RGC-5s
displayed localized TrkB-IR in the cell body (G, arrow), as compared to undifferentiated
RGC-5s. Merged image (H) demonstrates cellular localization of TrkB in differentiated
RGC-5s.
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Figure 4.
MSCs engineered with a lentiviral-BDNF vector produced bioactive BDNF. Embryonic dorsal
root ganglia (DRG) bioassay examining neurite outgrowth and density. When cultured with
standard MSC growth media the DRG elaborated few neurites (A). Likewise, GFP-MSC
conditioned media (CM) did not induce significant neurite outgrowth (B). However, when
DRG were cultured in either BDNF-MSC CM (C), or media containing rhBDNF (D),
significant neurite outgrowth was observed. Qualitative analysis using naïve observers (E)
revealed no significant difference in the neurite outgrowth scores for DRG grown in media, or
GFP-MSC conditioned media (p > 0.05). No significant difference was observed in neurite
outgrowth scores for DRG treated with BDNF-MSC CM, or rhBDNF. However, significantly
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greater neurite outgrowth scores in DRG treated with BDNF-MSC CM or rhBDNF was
observed when compared to DRG grown in either GFP-MSC CM or media alone (p < 0.05).
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Figure 5.
Differentiated RGC-5s are susceptible to glutamate and H2O2 induced cell death that can be
prevented with rhBDNF. Significant cell death can be induced in SS differentiated RGC-5s
with glutamate treatment at concentrations greater than 800 μM, as compared to vehicle treated,
control RGC-5s (A, p < 0.05). H2O2 also proved to be a potent inducer of significant cell death
at concentrations of 10 μM and greater (B, p < 0.05). Cell death induced by glutamate (C), or
H2O2 (D) could be attenuated by addition of rhBDNF at concentrations of 100 ng/ mL and
greater (p < 0.05), as compared to RGC-5s treated with glutamate or H2O2 only. Cell death
was confirmed in these experiments by application of Sytox, which labels dying cells. Control
RGC-5s had significantly less Sytox labeling than H2O2 or glutamate treated cells (E, p <
0.0001).
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Figure 6.
BDNF released from MSCs can protect RGC-5s from glutamate-mediated death. Following
treatment with 1 mM glutamate, only 57.29 ± 1.89 % of RGC-5s remained. When glutamate
treated RGC-5s were grown in the presence of BDNF-MSCs or rhBDNF significantly more
cells were present, compared to cultures not exposed to BDNF (A, p < 0.05). We have
demonstrated GFP-MSCs were not able to prevent RGC-5 cell loss following glutamate
treatment. Representative images are shown for control RGC-5s (B), RGC-5s exposed to 1
mM glutamate (C), and RGC-5s exposed to 1 mM glutamate and grown in the presence of
BDNF-MSCs (D) or GFP-MSCs (E).
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Figure 7.
BDNF released from MSCs can protect RGC-5s from H2O2 mediated cell death. Following
treatment with 10 μM H2O2, only 44.5 ± 2.2 % of RGC-5s were present, as compared to vehicle-
only treated cultures (A). When H2O2 treated RGC-5s were grown in the presence of BDNF-
MSCs or rhBDNF, a significantly greater percentage of cells were present, as compared to
RGC-5s grown in the presence of GFP-MSCs (p < 0.001). We have demonstrated less RGC-5s
present when grown in the presence of BDNF-MSCs, as compared to vehicle and GFP-exposed
cells. Representative images are shown for control RGC-5s (B), RGC-5s exposed to 10 μM
H2O2 (C), and RGC-5s exposed to H2O2 and grown in the presence of BDNF-MSCs (D) or
GFP-MSCs (E).
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